Karyopharm Therapeutics (KPTI) Cash from Operations (2012 - 2025)

Karyopharm Therapeutics has reported Cash from Operations for 14 years, with the latest figure at 11828000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations rose 54.17% year-over-year to 11828000.0; the trailing twelve-month figure through Dec 2025 stood at 75369000.0 (up 40.88% YoY), and the FY2025 full-year result was 75369000.0, up 40.88% from the prior year.
• Cash from Operations for Q4 2025 stood at 11828000.0, down from 5860000.0 in the prior quarter.
• The five-year high for Cash from Operations was 25475000.0 in Q4 2021, with the low at 59197000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 27612400.0 across 5 years, with a median of 26326500.0 in 2022.
• Annual changes were most pronounced in 2021 — Cash from Operations jumped 183.16% — and 2022, when it sank 205.37%.
• Karyopharm Therapeutics' Cash from Operations stood at 25475000.0 in 2021, then slumped by 205.37% to 26843000.0 in 2022, then soared by 30.76% to 18585000.0 in 2023, then tumbled by 38.88% to 25810000.0 in 2024, then soared by 54.17% to 11828000.0 in 2025.
• The last three Cash from Operations figures came in at 11828000.0 (Q4 2025), 5860000.0 (Q3 2025), and 18697000.0 (Q2 2025), per Business Quant data.